Home › Ovarian Epithelial Carcinoma › Virginia › Arlington
Ovarian Epithelial Carcinoma clinical trials in Arlington, VA
4 studies for Ovarian Epithelial Carcinoma are looking for participants at sites in and around Arlington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RecruitingPhase 2
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456, Fairfax · 11 mi away
Study of AVZO-021 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, Fairfax · 11 mi away
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
RecruitingPhase 3
- Research Site, Fairfax · 11 mi away
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RecruitingPhase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi away
Ovarian Epithelial Carcinoma trials in other cities
- Boston, MA8 studies
- Durham, NC8 studies
- New York City, NY7 studies
- San Diego, CA7 studies
- Chicago, IL7 studies
- Baltimore, MD6 studies
- Cleveland, OH6 studies
- Philadelphia, PA6 studies
- Houston, TX6 studies
- Portland, OR5 studies
- Minneapolis, MN5 studies
- Salt Lake City, UT5 studies
Other studies in Arlington
- Non-Small Cell Lung Cancer104 studies
- Metastatic Cancer53 studies
- Colorectal Cancer52 studies
- Cancer (all types)48 studies
- Breast Cancer47 studies
- Ovarian Cancer46 studies
- Lung Cancer41 studies
- Endometrial Cancer39 studies
- Pancreatic Cancer33 studies
- Head and Neck Squamous Cell Carcinoma26 studies
- Small Cell Lung Cancer23 studies
- Stomach Cancer20 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.